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ABSTRACT: Eﬃcient delivery of antigens is of paramount
concern in immunotherapies. We aimed to target antigen
presenting cells (APCs) by conjugating CpG oligonucleotides to
an E2 protein nanoparticle surface (CpG-PEG-E2). Compared to
E2 alone, we observed ∼4-fold increase of in vitro APC uptake of
both CpG-PEG-E2 and E2 conjugated to non-CpG DNA.
Furthermore, compared to E2-alone or E2 functionalized solely
with polyethylene glycol (PEG), the CpG-PEG-E2 showed
enhanced lymph node retention up to at least 48 h and 2-fold
increase in APC uptake in vivo, parameters which are advanta-
geous for vaccine success. This suggests that enhanced APC
uptake of nanoparticles mediated by oligonucleotide display may
help overcome delivery barriers in vaccine development.
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Though improved surgery, chemotherapy, and radiationtechniques should endure in the toolbox of oncologic
interventions,1 immunotherapies have emerged as a revolu-
tionary approach in cancer treatment, sprouting from an
increased understanding of cancer biology, the human genome,
and the immune system.2 Cancer immunotherapies engage
one’s own immune system for targeted tumor destruction,
eradication of metastases, and production of immunological
memory. Cancer vaccines have long been a strategy to elicit
antitumor immunity. Among the many challenges facing the
design of a cancer vaccine is an optimal delivery method.2
The ability to supply suﬃcient amounts of antigen and
immune-modulating compounds to the lymphatics is critical,3
and more speciﬁcally delivery to professional antigen presenting
cells (APCs), such as dendritic cells (DCs) that are responsible
for orchestration of the adaptive anticancer response.4
Engineered biomaterials, and in particular those that are
nanostructured,5 represent technologies that may help to
overcome antigen delivery problems.6 Nanoparticles naturally
access lymphatics following immunization and interact with
DCs and other APCs,3 which may be enhanced by displaying
DC-speciﬁc antibodies.7−9 Although antibodies are tremen-
dously speciﬁc to their target, they can be diﬃcult to produce
and would likely signiﬁcantly alter the physical size and
properties of the nanoparticle vaccine platform.7
Ideally, a simple-to-employ DC-speciﬁc targeting moiety
would be preferred for biomaterial design. Recently, the Toll-
like receptor (TLR) 9 agonist CpG (single-stranded non-
methylated oligodeoxynucleotides containing CG motifs) was
revealed as a possible ligand for DEC-205, an endocytic
receptor expressed mainly by DCs and other APCs.10 The
ﬁnding that DCs may possess receptors to detect CpG-
containing single-stranded DNA (ssDNA) presents the
opportunity to exploit a naturally occurring TLR ligand that
may also serve as an APC-targeting molecule for vaccine
delivery.
Our group has been developing the pyruvate dehydrogenase-
derived, self-assembling (60-mer) E2 caged protein nano-
particle for biomedical applications, including cancer immuno-
therapy.11−16 We have shown that E2 possesses the capability
to simultaneously deliver tumor antigens and CpG to DCs for
enhanced activation of antigen-speciﬁc CD8+ T cells, yielding
enhanced anticancer activity and increased survival time of
syngeneic tumor-bearing mice.12,14
Caged protein nanoparticles (e.g., E2, viruslike particles
[VLPs]) exhibit unique advantages over other nanoparticles for
immunotherapy,17,18 in that they represent a genetically
modiﬁable homogeneous platform that also exhibits a natural
tropism and the optimal geometry for interaction with APCs in
situ.3,17,19 Though E2 has been successfully applied in a murine
model, demonstrating strong potential in cancer immunother-
apy development,12,14 the in vivo fate of this platform has not
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been elucidated. In this study, our goals were to examine the
biodistribution of the E2 nanoparticle vaccine platform, and in
particular to investigate whether CpG display on E2 could
increase aﬃnity for DCs in secondary lymphoid organs.
E2 nanoparticles were conjugated with green ﬂuorescent dye
through non-native internal cavity cysteines (E2 mutant
D381C, herein simply abbreviated “E2”), in order to facilitate
tracking.11 For ligand display, we conjugated 5′ thiol-
terminated CpG 1826 or non-CpG ssDNA oligodeoxynucleo-
tide 1982 to solvent-exposed lysines on the E2 nanoparticle
surface via a bifunctional amine- and thiol-reactive poly-
(ethylene glycol) (PEG; average molecular weight 2000 Da)
linker. CpG 1826 is known to activate DCs, whereas non-CpG
1982 has served as a negative control for such prior
studies.20−23 These nanoparticles are abbreviated CpG-PEG-
E2 and (non-CpG)-PEG-E2, respectively. Methoxy-terminated
amine-reactive PEG conjugated to the surface-accessible lysines
on E2 served as a control devoid of DNA (mPEG-E2; average
PEG molecular weight of 2000 Da) (see Methods in the
Supporting Information). We have previously shown that
surface-bound 2000 Da PEG can inhibit cellular interaction
with E2 and may serve as a ﬂexible linker to facilitate ligand/
receptor interaction on cells.13,16 PEG linkers larger than 2000
Da have been shown to increase nanoparticle size and
polydispersity.8
We characterized our functionalized E2 to ensure that
external conjugation of CpG did not signiﬁcantly alter E2 size
or cause aggregation (Figure 1). SDS-PAGE of functionalized
E2 nanoparticles revealed protein between ∼30−40 kDa for
mPEG-E2, consistent with heterogeneous attachment of one or
more 2000 ± 200 Da PEGs per E2 subunit (Figure S1). For the
CpG-PEG-E2 and (non-CpG)-PEG-E2 samples, bands were
observed at ∼28 kDa (consistent with E2, no conjugation),
∼30−32 kDa (E2 + PEG, no attached CpG), and ∼35 kDa (E2
+ PEG + CpG), supporting a 60-mer particle with varying
degrees of conjugation. Bands at ∼60 kDa and above are
artifacts that are consistently observed when conjugating the
bifunctional PEG linker with E2,16 and this control is shown in
the lane of malPEG-E2 (Figure S1). Unreacted maleimides
were quenched with L-cysteine. We estimated a conjugation
ratio of 16 ± 5 CpG/E2 nanoparticle (Supporting
Information), within the range achieved for a synthetic
nanoparticle system, when adjusting for the diﬀerence in
particle diameter.24 Depending on the conformation of the
PEG (i.e., brush or mushroom), the polymer may not be fully
extended and the maleimide may not be easily accessible to
react with the thiol-terminated CpG.25
Dynamic light scattering (DLS) revealed no signiﬁcant
changes in average particle sizes (Figure 1), demonstrating that
conjugation of PEG and ssDNA to E2 did not cause large
increases in particle size or aggregation. Zeta potential
measurements showed modest shifts in nanoparticle surface
charge, relative to −12 ± 1 mV for bare E2 (Figure 1; Methods
in the Supporting Information). Furthermore, the measured
increase in negative surface charge of ssDNA-containing E2,
relative to the more neutral PEGylated E2, is consistent with
surface conjugation of DNA.
We examined the in vitro association of the ﬂuorescently
labeled nanoparticles (E2, PEGylated E2 [mPEG-E2], CpG
conjugated to E2 [CpG-PEG-E2], and non-CpG ssDNA
conjugated to E2 [(non-CpG)-PEG-E2]) with diﬀerent
representative cell types, including bone marrow-derived DCs
(BMDCs), bone marrow-derived macrophages (BMDMs), B
cells (CH12), T cells (B3Z), and ﬁbroblasts (NIH 3T3). As
expected, PEGylation (mPEG-E2) decreased uptake of E2 by
all cell types tested in vitro, relative to nonfunctionalized E2
(Figure 2), at multiple concentrations (Figure S2); this
Figure 1. Hydrodynamic diameter and surface charge characterization of nanoparticles. (A) Representative size distribution for E2, mPEG-E2, CpG-
PEG-E2, and (non-CpG)-PEG-E2 nanoparticles. (B) Average size and measured zeta potential of nanoparticles.
Figure 2. BMDCs and BMDMs show increased association with CpG-
PEG-E2 and (non-CpG)-PEG-E2 nanoparticles in vitro, compared to
their interactions with E2 and mPEG-E2. Cellular association was
measured by mean ﬂuorescence intensity (MFI) of cells incubated
with 5 μg/mL E2 nanoparticle for 1 h at 37 °C. Data are reported as
average ± SEM, relative to cellular background ﬂuorescence (PBS), of
3 independent experiments. Statistical signiﬁcance was determined
with one-way ANOVA using a post hoc Tukey’s test (*** p < 0.001).
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decrease is consistent with observations from our previously
published reports and with PEGylation of other VLPs.13,26
CpG-PEG-E2 exhibited increased association with APCs
relative to nonfunctionalized E2 (∼4-fold increase by BMDCs
and BMDMs [p < 0. 001], and to a lesser extent by B cells), but
not with T cells or ﬁbroblasts. Trypsinization (to remove
surface bound proteins) revealed that the majority of CpG-
PEG-E2 nanoparticles were internalized by BMDCs and
BMDMs, but not by B cells (Figure S3). We also observed
enhanced BMDC and BMDM uptake of E2 conjugated with
non-CpG-containing ssDNA (Figure 2), which was an
unexpected result; however, this may not be too unusual
given that certain cell receptors, such as DEC-205, have also
shown aﬃnity for both CpG and DNA sequences without
CpG.10
Although we expected increased CpG-PEG-E2 uptake by
DEC-205+ BMDC (DEC-205 expression in Figure S4), which
we did observe (Figure 2), it is also notable that there was
increased binding to DEC-205− BMDMs. It does make sense,
however, that APCs likely possess multiple external sensing
mechanisms for ssDNA, such as scavenger receptors,27,28
although isolating and identifying each receptor involved is
beyond the scope of the current study. In fact, examination of
CpG-PEG-E2 uptake revealed involvement of both clathrin-
mediated uptake and macropinocytosis, consistent with multi-
ple mechanisms, whereas uptake of E2 alone involved clathrin-
and actin-mediated endocytosis (Figure S5). Sensing of TLR
danger signals is known to transiently increase the macro-
pinocytic activity of DCs,29 consistent with our observation of
increased involvement of this uptake pathway toward CpG-
PEG-E2, although such a phenomenon is unlikely to explain
enhanced uptake of non-CpG ssDNA. Other eﬀects, such as
increased APC uptake of negatively charged nanoparticles, has
also been demonstrated by others, although the relatively small
degree of charge diﬀerences between nanoparticles in this study
is unlikely to solely account for the large diﬀerences in uptake
observed between CpG-PEG-E2 and E2 nanoparticles.30,31 In
any case, these results are the ﬁrst, to our knowledge, to
demonstrate signiﬁcantly increased uptake by DCs and
macrophages of nanoparticles functionalized with immunolog-
ically relevant ssDNA oligonucleotides, critical for increasing
eﬃcacy of modern vaccines for diseases like cancer.4,32
We then investigated whether the observed in vitro targeting
eﬀect mediated by display of ssDNA was evident in vivo in areas
of high APC-activity (i.e., lymph nodes) by measuring
ﬂuorescence (MFI) of cells from individual organs. Six hours
following subcutaneous administration (SC) in mice, the E2
nanoparticle was predominantly detected at the injection site,
within the lymph nodes (LNs) ipsilateral to injection site, and
to a lesser extent in the liver and spleen (Figure 3 and Figure
S6). Further inspection revealed the E2 nanoparticle was found
in 5 out of 7 LNs tested (injection site ipsilateral popliteal,
inguinal, axillary, iliac, and renal, but not ipsilateral cervical or
mesenteric; Figure 3). E2, mPEG-E2, and CpG-PEG-E2 were
undetectable in the thymus, kidney, heart, and lung (Figure
S6). Because of the similarity between cellular uptake data for
CpG-PEG-E2 and (non-CpG)-PEG-E2 nanoparticles in vitro,
only the former ssDNA-containing nanoparticle was examined
in vivo. PEGylation (mPEG-E2) and CpG display (CpG-PEG-
E2) on E2 exhibited a few notable changes in their in vivo fate,
in that CpG-PEG-E2 was the only nanoparticle not detectable
in the spleen (Figure 3) and mPEG-E2 was measured in the
blood (Figure S6) and in the contralateral lymph nodes (Figure
S7). Remarkably, 48 h following administration, the CpG-PEG-
Figure 3. Distribution of nanoparticles in the lymph nodes ipsilateral to injection site, mesenteric lymph node, and spleen following injection, after
(A) 6 h and (B) 48 h. E2, mPEG-E2, and CpG-PEG-E2 nanoparticles were administered subcutaneously. Mean ﬂuorescence intensity (MFI) was
measured by ﬂow cytometry of cells from relevant tissues, and background is MFI from PBS-injected mice. Data are presented as average ± SEM of
3 independent experiments.
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E2 nanoparticle was still evident in the ipsilateral LNs (Figure
3), whereas E2 and mPEG-E2 were largely undetectable.
These observations indicated that a PEGylated surface alone
allows the E2 nanoparticle to disperse further throughout the
lymphatic and circulatory system, in agreement with the
accepted properties of PEGylation in drug delivery systems,33
including VLPs.34,35 Display of CpG on the distal end of a
PEG-linker (CpG-PEG-E2) resulted in retention of the E2
nanoparticle within proximal areas that contain DC popula-
tions, an attractive quality for vaccine design and success.36,37
While CpG-PEG-E2 was not detected in the spleen, the
draining LNs (dLNs) have been shown to play the more critical
role in acute antiviral and anticancer responses.38
To determine whether accumulation and retention of CpG-
PEG-E2 nanoparticles within the dLNs was due to increased
aﬃnity for cells expressing DEC-205, we examined ﬂuorescence
of DEC-205+ dLN cells (i.e., popliteal, inguinal, axillary, iliac,
and renal LNs ipsilateral to injection site). However, consistent
with our in vitro data, we observed no signiﬁcant diﬀerence
between the average ﬂuorescence of DEC-205+ cells from mice
injected with CpG-PEG-E2, compared to E2 or mPEG-E2,
after either 6 or 48 h (Figure 4A, B).
Interestingly, however, the overall CD11c+ population
(primarily DCs) from the dLNs of the CpG-PEG-E2 group
showed a signiﬁcant 2-fold increased ﬂuorescence compared to
groups injected with E2 or mPEG-E2 nanoparticles (Figure
4C). This indicates increased broad DC association/uptake of
CpG-PEG-E2, critically important for cell-mediated vaccine
success,4 and in good agreement with our in vitro observations
(Figure 2 and Figure S2). We also observed a modest increase
in CpG-PEG-E2 ﬂuorescence of F4/80+ cells, compared to
groups given E2 or mPEG-E2 (Figure 4C). Altogether, our in
vivo data suggest that decoration of the E2 nanoparticle with
CpG oligonucelotides enhances physical association and/or
uptake by DCs and macrophages within the dLNs following SC
injection.
Of the total CD11c+ (primarily DCs) and F4/80+ (macro-
phages and Langerhans DCs) cell populations from the dLNs,
∼50% were associated with E2, mPEG-E2, and CpG-PEG-E2
(Figure S8), a relatively high percentage compared to other
nanoparticle studies, including other VLPs.39,40 All of the E2
nanoparticles tested were also associated, although to a much
lesser extent, with CD3+ (T cells) and B220+ cells (B cells and
plasmacytoid DCs), but interestingly showed no diﬀerences in
cellular association based on nanoparticle surface chemistry
(Figure S8). These results demonstrated that decoration of E2
with CpG (or PEG) did not signiﬁcantly alter speciﬁcity for any
particular cell type. Rather, a likely explanation for our observed
increase in LN ﬂuorescence of CpG-PEG-E2-injected mice may
be due to general elevated overall nanoparticle uptake (Figure
4C). In any case, there appears to be a clear advantage for the
delivery of E2 nanoparticles decorated externally with CpG
molecules, from the metric of increased in vivo LN retention
(Figure 3) and APC association (Figure 4C), which are
attractive qualities of a cancer vaccine delivery system.36,37
Here, we have demonstrated that surface display of CpG-
containing ssDNA oligonucleotides signiﬁcantly increased
APC-speciﬁc uptake of the E2 nanoparticle. In vitro ssDNA
decoration induced large increases in cellular uptake of E2 by
DCs and macrophages. In vivo, the CpG-PEG-E2 nanoparticle
showed a signiﬁcant increase in cellular association with DCs
within the dLNs, compared to the other nanoparticles tested.
These increased interactions in the presence of surface-bound
ssDNA oligos, including CpG, appear to operate through
multiple mechanisms. Further, CpG-PEG-E2 also demonstra-
ted increased LN retention over 48 h, and less presence in
blood draining organs, compared to the E2 and mPEG-E2
nanoparticles. Overall, these results demonstrate that deco-
ration of protein-based nanoparticles with CpG can increase
lymph node retention and uptake by APCs, factors that are
beneﬁcial in vaccine design.
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